CPT-11, which has been shown to have great efficacy in anticancer therapy and is being used as the first line treatment for colorectal cancer, has recently been reported to activate the NLRP3 inflammasome through JNK signaling in macrophages46. The gene discussed is MAPK8; the disease is colorectal cancer.